Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11909979
Wiggin GR, et al. (2002) MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22, 2871-81 11909979
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S63-p - ATF-1 (mouse)
Modsite: GILARRPsYRKILKD SwissProt Entrez-Gene
Orthologous residues
ATF‑1 (human): S63‑p, ATF‑1 (mouse): S63‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2]
Cellular systems studied:  primary cultured cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
PD184352 phorbol_ester inhibit treatment-induced increase
SB203580 phorbol_ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol_ester inhibit treatment-induced increase
EGF increase
PD184352 EGF inhibit treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
SB203580, PD184352 EGF inhibit treatment-induced increase
UV increase
PD184352 UV no effect upon treatment-induced increase
SB203580 UV inhibit treatment-induced increase
SB203580, PD184352 UV inhibit treatment-induced increase
anisomycin increase WT
anisomycin MSK1 (mouse) inhibit treatment-induced increase KO
anisomycin MSK2 (mouse) no effect upon treatment-induced increase
anisomycin MSK1 (mouse), MSK2 (mouse) inhibit treatment-induced increase double KO
UV increase WT
anisomycin MSK1 (mouse) inhibit treatment-induced increase KO
UV MSK2 (mouse) no change compared to control KO
UV MSK1 (mouse), MSK2 (mouse) inhibit treatment-induced increase double KO
phorbol_ester increase WT
phorbol_ester MSK1 (mouse) inhibit treatment-induced increase KO
phorbol_ester MSK2 (mouse) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) increase double KO
EGF increase WT
EGF MSK1 (mouse) inhibit treatment-induced increase KO
EGF MSK2 (mouse) inhibit treatment-induced increase KO
EGF MSK1 (mouse), MSK2 (mouse) inhibit treatment-induced increase double KO
colforsin, IBMX inhibit treatment-induced decrease WT
colforsin, IBMX MSK1 (mouse) no effect upon treatment-induced increase KO
colforsin, IBMX MSK2 (mouse) no effect upon treatment-induced increase KO
colforsin, IBMX MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
MSK1 (mouse), MSK2 (mouse) no change compared to control double KO
PD184352 MSK1 (mouse), MSK2 (mouse) no change compared to control
phorbol_ester MSK1 (mouse), MSK2 (mouse) increase
PD184352 phorbol_ester inhibit treatment-induced increase
SB203580 phorbol_ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol_ester inhibit treatment-induced increase
Ro31-8220 phorbol_ester inhibit treatment-induced increase
H-89 phorbol_ester no effect upon treatment-induced increase

S133-p - CREB (mouse)
Modsite: EILsRRPsyRkILND SwissProt Entrez-Gene
Orthologous residues
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2]
Cellular systems studied:  primary cultured cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
PD184352 phorbol_ester inhibit treatment-induced increase
SB203580 phorbol_ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol_ester inhibit treatment-induced increase
EGF increase
PD184352 EGF inhibit treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
SB203580, PD184352 EGF inhibit treatment-induced increase
UV increase
PD184352 UV no effect upon treatment-induced increase
SB203580 UV inhibit treatment-induced increase
SB203580, PD184352 UV inhibit treatment-induced increase
anisomycin increase WT
anisomycin MSK1 (mouse) inhibit treatment-induced increase KO
anisomycin MSK2 (mouse) no effect upon treatment-induced increase
anisomycin MSK1 (mouse), MSK2 (mouse) inhibit treatment-induced increase double KO
UV increase WT
anisomycin MSK1 (mouse) inhibit treatment-induced increase KO
UV MSK2 (mouse) no change compared to control KO
UV MSK1 (mouse), MSK2 (mouse) inhibit treatment-induced increase double KO
phorbol_ester increase WT
phorbol_ester MSK1 (mouse) inhibit treatment-induced increase KO
phorbol_ester MSK2 (mouse) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) increase double KO
EGF increase WT
EGF MSK1 (mouse) inhibit treatment-induced increase KO
EGF MSK2 (mouse) inhibit treatment-induced increase KO
EGF MSK1 (mouse), MSK2 (mouse) inhibit treatment-induced increase double KO
colforsin, IBMX inhibit treatment-induced decrease WT
colforsin, IBMX MSK1 (mouse) no effect upon treatment-induced increase KO
colforsin, IBMX MSK2 (mouse) no effect upon treatment-induced increase KO
colforsin, IBMX MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
MSK1 (mouse), MSK2 (mouse) no change compared to control double KO
PD184352 MSK1 (mouse), MSK2 (mouse) no change compared to control
phorbol_ester MSK1 (mouse), MSK2 (mouse) increase
PD184352 phorbol_ester inhibit treatment-induced increase
SB203580 phorbol_ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol_ester inhibit treatment-induced increase
Ro31-8220 phorbol_ester inhibit treatment-induced increase
H-89 phorbol_ester no effect upon treatment-induced increase

T203-p - ERK1 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2]
Cellular systems studied:  primary cultured cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
PD184352 phorbol_ester inhibit treatment-induced increase
SB203580 phorbol_ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol_ester inhibit treatment-induced increase
EGF increase
PD184352 EGF inhibit treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
SB203580, PD184352 EGF inhibit treatment-induced increase
UV increase
PD184352 UV inhibit treatment-induced increase
SB203580 UV no effect upon treatment-induced increase
SB203580, PD184352 UV inhibit treatment-induced increase
anisomycin increase
PD184352 anisomycin inhibit treatment-induced increase
SB203580 anisomycin no effect upon treatment-induced increase
SB203580, PD184352 anisomycin inhibit treatment-induced increase
phorbol_ester increase WT
phorbol_ester phorbol_ester MSK1 (human) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
EGF increase WT
EGF MSK1 (mouse) no effect upon treatment-induced increase KO
EGF MSK2 (mouse) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
UV increase WT
UV MSK1 (mouse) no effect upon treatment-induced increase KO
UV MSK2 (mouse) no effect upon treatment-induced increase KO
UV MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
anisomycin increase WT
anisomycin MSK1 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK2 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2]
Cellular systems studied:  primary cultured cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
PD184352 phorbol_ester inhibit treatment-induced increase
SB203580 phorbol_ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol_ester inhibit treatment-induced increase
EGF increase
PD184352 EGF inhibit treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
SB203580, PD184352 EGF inhibit treatment-induced increase
UV increase
PD184352 UV inhibit treatment-induced increase
SB203580 UV no effect upon treatment-induced increase
SB203580, PD184352 UV inhibit treatment-induced increase
anisomycin increase
PD184352 anisomycin inhibit treatment-induced increase
SB203580 anisomycin no effect upon treatment-induced increase
SB203580, PD184352 anisomycin inhibit treatment-induced increase
phorbol_ester increase WT
phorbol_ester phorbol_ester MSK1 (human) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
EGF increase WT
EGF MSK1 (mouse) no effect upon treatment-induced increase KO
EGF MSK2 (mouse) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
UV increase WT
UV MSK1 (mouse) no effect upon treatment-induced increase KO
UV MSK2 (mouse) no effect upon treatment-induced increase KO
UV MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
anisomycin increase WT
anisomycin MSK1 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK2 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2]
Cellular systems studied:  primary cultured cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
PD184352 phorbol_ester inhibit treatment-induced increase
SB203580 phorbol_ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol_ester inhibit treatment-induced increase
EGF increase
PD184352 EGF inhibit treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
SB203580, PD184352 EGF inhibit treatment-induced increase
UV increase
PD184352 UV inhibit treatment-induced increase
SB203580 UV no effect upon treatment-induced increase
SB203580, PD184352 UV inhibit treatment-induced increase
anisomycin increase
PD184352 anisomycin inhibit treatment-induced increase
SB203580 anisomycin no effect upon treatment-induced increase
SB203580, PD184352 anisomycin inhibit treatment-induced increase
phorbol_ester increase WT
phorbol_ester phorbol_ester MSK1 (human) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
EGF increase WT
EGF MSK1 (mouse) no effect upon treatment-induced increase KO
EGF MSK2 (mouse) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
UV increase WT
UV MSK1 (mouse) no effect upon treatment-induced increase KO
UV MSK2 (mouse) no effect upon treatment-induced increase KO
UV MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
anisomycin increase WT
anisomycin MSK1 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK2 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2]
Cellular systems studied:  primary cultured cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
PD184352 phorbol_ester inhibit treatment-induced increase
SB203580 phorbol_ester no effect upon treatment-induced increase
SB203580, PD184352 phorbol_ester inhibit treatment-induced increase
EGF increase
PD184352 EGF inhibit treatment-induced increase
SB203580 EGF no effect upon treatment-induced increase
SB203580, PD184352 EGF inhibit treatment-induced increase
UV increase
PD184352 UV inhibit treatment-induced increase
SB203580 UV no effect upon treatment-induced increase
SB203580, PD184352 UV inhibit treatment-induced increase
anisomycin increase
PD184352 anisomycin inhibit treatment-induced increase
SB203580 anisomycin no effect upon treatment-induced increase
SB203580, PD184352 anisomycin inhibit treatment-induced increase
phorbol_ester increase WT
phorbol_ester phorbol_ester MSK1 (human) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
EGF increase WT
EGF MSK1 (mouse) no effect upon treatment-induced increase KO
EGF MSK2 (mouse) no effect upon treatment-induced increase KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
UV increase WT
UV MSK1 (mouse) no effect upon treatment-induced increase KO
UV MSK2 (mouse) no effect upon treatment-induced increase KO
UV MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
anisomycin increase WT
anisomycin MSK1 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK2 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO

T180-p - P38A (mouse)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2]
Cellular systems studied:  primary cultured cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester no change compared to control WT
phorbol_ester MSK1 (mouse) no change compared to control KO
phorbol_ester MSK2 (mouse) no change compared to control KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no change compared to control double KO
EGF no change compared to control WT
EGF MSK1 (mouse) no change compared to control KO
EGF MSK2 (mouse) no change compared to control KO
EGF MSK1 (mouse), MSK2 (mouse) no change compared to control double KO
UV increase WT
UV MSK1 (mouse) no effect upon treatment-induced increase KO
UV MSK2 (mouse) no effect upon treatment-induced increase KO
UV MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
anisomycin increase WT
anisomycin MSK1 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK2 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO

Y182-p - P38A (mouse)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2]
Cellular systems studied:  primary cultured cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester no change compared to control WT
phorbol_ester MSK1 (mouse) no change compared to control KO
phorbol_ester MSK2 (mouse) no change compared to control KO
phorbol_ester MSK1 (mouse), MSK2 (mouse) no change compared to control double KO
EGF no change compared to control WT
EGF MSK1 (mouse) no change compared to control KO
EGF MSK2 (mouse) no change compared to control KO
EGF MSK1 (mouse), MSK2 (mouse) no change compared to control double KO
UV increase WT
UV MSK1 (mouse) no effect upon treatment-induced increase KO
UV MSK2 (mouse) no effect upon treatment-induced increase KO
UV MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO
anisomycin increase WT
anisomycin MSK1 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK2 (mouse) no effect upon treatment-induced increase KO
anisomycin MSK1 (mouse), MSK2 (mouse) no effect upon treatment-induced increase double KO